ICAP at Columbia University has received 25 million dollars in the first year of a $125 million, five-year award from the U.S. Centers for Disease Control and Prevention to conduct national, population-based HIV impact assessments (PHIAs) in 20 countries in sub-Saharan Africa. These surveys will provide critical information on the state of the HIV epidemic in these countries and help shape policies and programs to confront the epidemic. The findings may also help inform global funding priorities.
Listen to ICAPs’ Grand Rounds Webinar, “Ebola: This Time Is Different.” Available here.
ICAP has been awarded funding from National Institutes of Health (NIH) to participate in a new clinical research study by the HIV Prevention Trials Network that will evaluate the safety and acceptability of a new injectable HIV prevention medication, TMC278 LA (long acting), a long acting formulation of the drug Rilpivirine, for use in healthy, HIV-uninfected women.
As the global response to HIV advances, and programs mature from an emergency to a sustained response, greater focus is being dedicated to quality and quality improvement (QI). The emphasis on QI is based on the appreciation of the importance of quality in achieving program effectiveness at a population level.
Gillian Dougherty, one of ICAP’s experts in quality improvement, leads a new QI course and works directly with public health professionals on the challenges they face in advancing quality in their programs. Here she shares the basics of quality improvement and outlines the importance of high quality programs to reaching new HIV prevention, care, and treatment goals.
Text Here When Maselobe Lebona was a nursing student at the National University of Lesotho (NUL), she often became nervous when she had to perform procedures on patients for the first time. Because she did not have an opportunity to practice certain skills in a clinical simulation setting, such as drawing blood, she was anxious and often unable to accomplish the task. Some patients only allowed her one chance. “This was a problem because hardly any students would get it right on the first attempt,” said Lebona, now a clinical supervisor at NUL. For patients with HIV, this can be particularly distressing as results determine when they will begin life-saving medications.
This month, ICAP and the Department of Epidemiology at the Mailman School of Public Health welcomed five Global HIV Implementation Science Research Fellows. The program will ready three pre-doctoral and two post-doctoral fellows for careers as independently-funded researchers.
We are pleased to welcome: Eleanor Hayes-Larson, Stephanie Kujawski, Anton Palma, Dr. Ayesha Sania and Dr. Matthew Thomann